Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ± Bevacizumab Versus Placebo Plus FOLFIRI ± Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Trial Profile

Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ± Bevacizumab Versus Placebo Plus FOLFIRI ± Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Veliparib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 14 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 27 Apr 2017 Planned End Date changed from 1 May 2017 to 18 Aug 2017.
    • 27 Apr 2017 Planned primary completion date changed from 1 May 2017 to 19 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top